Kim Popovits joins Rhythm (NASDAQ: RYTM) board as Ed Mathers exits
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Rhythm Pharmaceuticals reported changes to its Board of Directors. On April 1, 2026, the Board elected industry veteran Kimberly J. Popovits as a non-employee Class II director, with her term running until the 2028 annual meeting of stockholders. She will receive compensation under the existing non-employee director policy and enter the company’s standard indemnification agreement.
On the same date, long-serving director Edward T. Mathers resigned from the Board, with the company stating his resignation was not due to any disagreement over operations, policies or practices. Rhythm highlights its commercial-stage rare disease focus built around IMCIVREE (setmelanotide), an MC4R agonist approved for specific rare obesity indications in the United States, European Union and United Kingdom.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
New director term end: 2028 annual meeting
Industry experience: More than 40 years
Adverse adrenal insufficiency rate: 5% of IMCIVREE-treated patients
+5 more
8 metrics
New director term end
2028 annual meeting
Class II director term for Kimberly J. Popovits
Industry experience
More than 40 years
Kim Popovits’ life sciences leadership background
Adverse adrenal insufficiency rate
5% of IMCIVREE-treated patients
Acute adrenal insufficiency in acquired hypothalamic obesity with secondary adrenal insufficiency
Hyponatremia incidence
6% IMCIVREE vs 2% placebo
Patients with acquired hypothalamic obesity and central diabetes insipidus
Hypernatremia incidence
5% IMCIVREE vs 4% placebo
Patients with acquired hypothalamic obesity and central diabetes insipidus
Common adverse reaction threshold
≥20% incidence
Frequency cutoff for most common IMCIVREE adverse reactions in at least one indication
Minimum age U.S. acquired HO
4 years and older
Setmelanotide indication for acquired hypothalamic obesity
Minimum age genetic obesity
2 years and older
Setmelanotide indication for BBS or POMC, PCSK1, LEPR deficiency
Key Terms
Class II director, acquired hypothalamic obesity, Bardet-Biedl syndrome, MC4R agonist, +2 more
6 terms
Class II director regulatory
"Ms. Popovits will serve as a Class II director to hold office until the Company’s 2028 annual meeting"
A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.
acquired hypothalamic obesity medical
"adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity"
A condition in which damage to the brain’s hypothalamus—often from surgery, injury, or a tumor—disrupts the body’s internal “thermostat” for hunger, metabolism and energy use, causing rapid, hard-to-control weight gain. Investors care because it creates a clearly defined patient group with high unmet medical need, predictable clinical outcomes, and potential demand for therapies or devices; progress or setbacks in treating this condition can drive valuation swings for companies developing targeted treatments.
Bardet-Biedl syndrome medical
"adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS)"
A rare inherited disorder caused by mutations in genes that act like a blueprint for the body, leading to a constellation of problems such as progressive vision loss, kidney dysfunction, obesity, extra fingers or toes, and developmental delays. Investors track it because treating or diagnosing the condition can create focused markets for drugs, genetic tests, medical devices, and long-term care services, and because clinical trial outcomes and regulatory decisions for therapies can materially affect company value.
MC4R agonist medical
"Rhythm’s lead asset, IMCIVREE (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity"
A MC4R agonist is a drug that activates the melanocortin-4 receptor, a protein in the brain that helps regulate appetite, body weight and energy use. Think of it like turning down a hunger thermostat or nudging the body’s energy balance toward burning more fuel; that biological effect can produce weight loss or metabolic changes. Investors watch these drugs because successful trials or approvals can create large markets, while failures or side effects can sharply affect company value.
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
secondary adrenal insufficiency medical
"Patients with acquired HO and secondary adrenal insufficiency reported serious adverse reactions related to acute adrenal insufficiency"
FAQ
What board changes did Rhythm Pharmaceuticals (RYTM) announce?
Rhythm Pharmaceuticals added Kim Popovits as a non-employee Class II director and accepted the resignation of director Edward T. Mathers. The company emphasized that Mathers’s departure was not due to any disagreement over operations, policies or practices, signaling a planned transition.
Who is Kim Popovits, the new director at Rhythm Pharmaceuticals (RYTM)?
Kim Popovits is a life sciences leader with more than 40 years of healthcare experience. She previously served as Chairman, CEO and President of Genomic Health, led commercialization of Oncotype DX, held senior roles at Genentech, and now serves on several life sciences boards and advises Blackstone Life Sciences.
How long will Kim Popovits serve on Rhythm Pharmaceuticals’ board?
Kim Popovits was elected as a Class II director to serve until Rhythm Pharmaceuticals’ 2028 annual meeting of stockholders. She will continue in this role until that meeting and until a successor is duly elected and qualified or she departs earlier under normal governance provisions.
Why did Edward T. Mathers resign from Rhythm Pharmaceuticals’ board?
Edward T. Mathers resigned from Rhythm Pharmaceuticals’ Board of Directors effective April 1, 2026. The company stated his resignation was not caused by any disagreement regarding its operations, policies, or practices, suggesting an orderly governance change rather than a dispute-driven departure.
What is Rhythm Pharmaceuticals’ lead product IMCIVREE (setmelanotide)?
IMCIVREE (setmelanotide) is an MC4R agonist designed to treat hyperphagia and severe obesity in certain rare neuroendocrine conditions. It is approved in the U.S., European Union and United Kingdom for specific genetically defined or acquired obesity syndromes, targeting patients as young as 2 or 4 years, depending on indication.
For which patients is setmelanotide indicated in the United States?
In the United States, setmelanotide is indicated to reduce excess body weight and maintain weight reduction long term in adults and children aged 4 years and older with acquired hypothalamic obesity, and in adults and children 2 years and older with BBS or genetically confirmed POMC, PCSK1, or LEPR deficiency.
What key safety concerns are highlighted for IMCIVREE (setmelanotide)?
Important safety information includes risks of sexual arousal disturbances, depression and suicidal ideation, serious hypersensitivity reactions, skin hyperpigmentation and changes in nevi, acute adrenal insufficiency in acquired hypothalamic obesity, and sodium imbalance in patients with central diabetes insipidus, requiring careful monitoring and possible treatment adjustments.